Introducing Dr. Stephen Huhn Our New CMO at Dunad Therapeutics

Dunad Therapeutics is excited to welcome Stephen Huhn, MD, as our Chief Medical Officer.   Dr. Huhn’s experience leading early translational, clinical, and regulatory strategy for complex neurodegenerative disorders marks a significant step forward as Dunad moves our development candidate into IND-enabling studies and prepares to transition into a clinical stage company.  

Dr. Huhn has led early and mid-stage clinical development covering a wide range of neuroscience indications, therapeutic strategies, and first-in-human studies with small molecules, as well as novel complex platforms. He has C-suite experience with securing large pharma partnerships as well as navigation of a recent successful IPO. Dr. Huhn has successfully directed innovative clinical programs in neurodegenerative targets with high unmet need, and built highly effective clinical operations and development teams.  Prior to joining the industry, Dr Huhn was a faculty member in the Department of Neurological Surgery at Stanford University, and served as Chief of Pediatric Neurosurgery at Packard Children’s Hospital. 

“I am very excited to join the team at Dunad Therapeutics and look forward to advancing its strong discovery efforts into the clinic for ALS, as well as other related neurodegenerative diseases,” said Dr. Huhn. “Recent scientific advances in the field of neurodegeneration hold great promise for emerging therapeutics, especially those being developed at Dunad.”